New approval for Roche and Chugai's Ronapreve in Japan

5 November 2021
japan_big

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has received an approval from its national medicines regulator for Ronapreve (casirivimab/imdevimab).

Having obtained exclusive commercialization rights in Japan from Roche (ROG: SIX), Chugai secured regulatory approval in July 2021 for the antibody cocktail as a treatment for infection with coronavirus.

The new approval from Japan’s Ministry of Health, Labor and Welfare (MHLW) allows high-risk individuals who have tested positive or who have been in close contact with COVID-19 patients to be treated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology